A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with head and neck squamous cell carcinoma (HNSCC) (Pegasus Head and Neck 204) - ACT16903

Genzyme Europe BV0 个研究点目标入组 7 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- Participants must be >= 18 years of age inclusive, at the time of signing the
•informed consent
•- Histologically or cytologically confirmed diagnosis of R/M HNSCC that is
•considered not amenable to further therapy with curative intent. The eligible
•primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx
•(nasopharynx is excluded)
•- Measurable disease
•- Baseline biopsy must be submitted for all cohort A1, A2 Core Phase
•participants
•- Baseline biopsy must be submitted for all cohort B1, B2 Expansion Phase
•participants
•- Known HPV p16 status for oropharyngeal cancer
•- Participant agrees to follow protocol-specified contraception guidelines

•Participants are excluded from the study if any of the following criteria apply:
•- Eastern Cooperative Oncology Group (ECOG) performance status of >=2
•- Has received prior IL2-based anticancer treatment
•- For participants in Cohorts A1, A2: Prior treatment with an agent (approved or
•investigational) that blocks the PD-1/PD-L1 pathway (participants who joined a
•study with an anti-PD-1/PD-L1 in the experimental arm but have written
•confirmation they have not received anti-PD-1/PD-L1 are allowed)
•- For participants in Cohorts A2, B2: Prior treatment with cetuximab (prior
•cetuximab allowed if used for the treatment of locally advanced disease, with
•no progressive disease for at least 4 months from completion of prior cetuximab
•- For participants in Cohorts A2, B2: Electrolytes (magnesium, calcium,
•potassium) outside the normal ranges
•- Participants under anti-hypertensive treatment who cannot temporarily (for at
•least 36 hours) withhold antihypertensive medications prior to each IMP dosing
•- Participants with baseline SpO2 <=92% (without oxygen therapy)
•- Comorbidity requiring corticosteroid therapy (>10 mg prednisone/day or
•equivalent) within 2 weeks of IMP initiation. Inhaled or topical steroids are
•permitted, provided that they are not for treatment of an autoimmune disorder.
•Participants who require a brief course of steroids (eg, as prophylaxis for
•imaging studies due to hypersensitivity to contrast agents) are not excluded.

发起方